Your browser doesn't support javascript.
loading
Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study.
Miedema, Jelle R; Moor, Catharina C; Veltkamp, Marcel; Baart, Sara; Lie, Natascha S L; Grutters, Jan C; Wijsenbeek, Marlies S; Mostard, Rémy L M.
Afiliação
  • Miedema JR; Department of Pulmonology, Center of Excellence for Interstitial Lung Disease and Sarcoidosis, Erasmus University Medical Center, Rotterdam, The Netherlands. j.miedema@erasmusmc.nl.
  • Moor CC; Department of Pulmonology, Center of Excellence for Interstitial Lung Disease and Sarcoidosis, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Veltkamp M; Department of Pulmonology, ILD Center of Excellence, St. Antonius Hospital, Nieuwegein, The Netherlands.
  • Baart S; Division of Heart and Lungs, University Medical Center, Utrecht, The Netherlands.
  • Lie NSL; Department of Biostatistics, Erasmus MC, Rotterdam, The Netherlands.
  • Grutters JC; Department of Pulmonology, Zuyderland Medical Center, Heerlen, Sittard, The Netherlands.
  • Wijsenbeek MS; Department of Pulmonology, ILD Center of Excellence, St. Antonius Hospital, Nieuwegein, The Netherlands.
  • Mostard RLM; Division of Heart and Lungs, University Medical Center, Utrecht, The Netherlands.
Respir Res ; 23(1): 139, 2022 May 28.
Article em En | MEDLINE | ID: mdl-35643466

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asbestose / Fibrose Pulmonar Idiopática Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies Limite: Humans Idioma: En Revista: Respir Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asbestose / Fibrose Pulmonar Idiopática Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies Limite: Humans Idioma: En Revista: Respir Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda